Initial clinical characterization of novel proximal biomarkers for Nx-1607, a first-inclass oral Cbl-B inhibitor, in patients with advanced malignancies
Whelan, S. Karim, C. Ye, J. Ingallinera, T. Cherala, G. Jameson, K. Williams, A. Sharp, A. Krebs, Matthew G Pacey, S.
Whelan, S.
Karim, C.
Ye, J.
Ingallinera, T.
Cherala, G.
Jameson, K.
Williams, A.
Sharp, A.
Krebs, Matthew G
Pacey, S.
Citations
Altmetric:
Abstract
Authors
Whelan, S.
Karim, C.
Ye, J.
Ingallinera, T.
Cherala, G.
Jameson, K.
Williams, A.
Sharp, A.
Krebs, Matthew G
Pacey, S.
Blagden, S.
Plummer, R.
Hochhauser, D.
Evans, J.
De Bono, J.
Powers, J.
Karim, C.
Ye, J.
Ingallinera, T.
Cherala, G.
Jameson, K.
Williams, A.
Sharp, A.
Krebs, Matthew G
Pacey, S.
Blagden, S.
Plummer, R.
Hochhauser, D.
Evans, J.
De Bono, J.
Powers, J.
Affiliation
Nurix Therapeutics, Inc., San Francisco, CA,
Description
Date
2022
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Whelan S, Karim C, Ye J, Ingallinera T, Cherala G, Jameson K, et al. Initial Clinical Characterization of Novel Proximal Biomarkers for Nx-1607, a First-Inclass Oral Cbl-B Inhibitor, in Patients with Advanced Malignancies. Journal for immunotherapy of cancer. 2022 Nov;10:A809-A. PubMed PMID: WOS:000919423400733.